
Featured
GSK Finalizes Landmark $2 Billion Acquisition of BP Asset IX to Bolster Hepatology Pipeline
GSK has finalized a landmark $2 billion acquisition of Boston Pharmaceuticals' subsidiary, BP Asset IX, to secure the phase III-ready liver disease dr...
Read Full Story →